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Epidemiological aspects of Parkinson’s disease (PD), co-occurring diseases and medical
healthcare utilization of PD patients are still largely elusive. Based on claims data of 3.7
million statutory insurance members in Germany in 2015 the prevalence and incidence of
PD was determined. PD cases had at least one main hospital discharge diagnosis of PD,
or one physician diagnosis confirmed by a subsequent or independent diagnosis or by
PD medication in 2015. Prevalence of (co-)occurring diseases, mortality, and healthcare
measures in PD cases and matched controls were compared. In 2015, 21,714 prevalent
PD cases (standardized prevalence: 511.4/100,000 persons) and 3,541 incident PD
cases (standardized incidence: 84.1/100,000 persons) were identified. Prevalence of
several (co-)occurring diseases/complications, e.g., dementia (PD/controls: 39/13%),
depression (45/22%), bladder dysfunction (46/22%), and diabetes (35/31%), as well as
mortality (10.7/5.8%) differed between PD cases and controls. The annual healthcare
utilization was increased in PD cases compared to controls, e.g., regarding mean ±
SD physician contacts (15.2 ± 7.6/12.2 ± 7.3), hospitalizations (1.3 ± 1.8/0.7 ±
1.4), drug prescriptions (overall: 37.7 ± 24.2/21.7 ± 19.6; anti-PD medication: 7.4
± 7.4/0.1 ± 0.7), assistive/therapeutic devices (47/30%), and therapeutic remedies
(57/16%). The standardized prevalence and incidence of PD in Germany as well
as mortality in PD may be substantially higher than reported previously. While
frequently diagnosed with co-occurring diseases/complications, such as dementia,
depression, bladder dysfunction and diabetes, the degree of healthcare utilization shows
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large variability between PD patients. These findings encourage a rethinking of the
epidemiology and healthcare utilization in PD, at least in Germany. Longitudinal studies
of insurance claims data should further investigate the individual and epidemiological
progression and healthcare demands in PD.
Keywords: Parkinson’s disease, epidemiology, insurance claims, mortality, incidence, prevalence, comorbidity,
healthcare
INTRODUCTION
Parkinson’s disease (PD) is a common, chronic and progressive
neurodegenerative disease often leading to disability, care
dependency, reduced quality of life and premature death
(1). Moreover, PD is a complex and heterogeneous disease
regarding disease etiologies, presentation of symptoms and
disease progression (2, 3). In addition to cardinal motor
symptoms several non-motor symptoms and comorbidities,
such as dementia, depression, and autonomous dysfunction,
often affect patients with PD (4–6). Consequently, PD with
its associated diseases and complications, and their individual
progression over time pose specific, and often complex and
multi-faceted management demands. The personal needs of
PD patients require professional and patient-centered medical
treatment and healthcare support (7).
Despite its relevance there is paucity of recent and real-
world estimates of the epidemiology of PD, medical treatment
practice and other aspects of healthcare utilization and support
of PD patients in Germany. In this context, insurance claims
could serve as data basis for gaining insight into the recent
epidemiological status of PD including associated diseases and
complications as well as the real-world utilization of PD
treatments and healthcare services. Thus far, such estimates are
often difficult to compare between studies and/or nations as
data sources, i.e., primary and secondary data, and diagnostic
and inclusion criteria differ (8, 9) and may change over time
(10). Consequently, the status of the epidemiology of PD and
PD healthcare in Germany and across Europe remains elusive.
Both of these aspects should be investigated within one large,
recent and national dataset while applying previously used PD
case identification criteria, and while investigating PD as a
heterogeneous disease with frequently co-occurring/co-morbid
diseases/complications.
In Germany epidemiological estimates may be outdated and
restricted to elderly individuals [data from 2006, individuals aged
65+ years (11); data from 2004/2007, aged 50+ years (12)].
“Official” reports (7) of prevalence estimates of PD in Germany
still refer to estimates by the European Brain Council in 2010
that were however interpolated from prevalences reported for
Spain, France, Italy, and UK (13). In addition to the nation-wide
prevalence and incidence of PD, health claims data may provide
the real-world healthcare utilization of PD patients as important
for informed decision-making in healthcare policy and planning.
The present study of the MoPED consortium (Morbus
Parkinson Epidemiologie in Deutschland) aimed to (1) provide
standardized estimates of the PD prevalence and incidence in
Germany in 2015, (2) investigate the prevalence of (co-)occurring
diseases/complications and mortality in patients with and
without PD, and (3) quantify the real-world PD treatment and
healthcare utilization in Germany.
METHODS
Data Source
This study was based on the InGef research database,
which contains anonymized patient-level claims data from
approximately 6.7 million insured members of several German
statutory health insurances. In brief, the database includes
demographic information, ambulatory services and diagnoses,
hospital data including diagnoses and procedures, reimbursed
remedies and aids as well as dispensations of reimbursed drugs.
External validity of this database against German population
data has been shown previously (14). To create a representative
sample regarding the age and sex distribution in Germany and to
increase the generalizability of findings, a sample of ∼4 million
insured persons (4.5% of German population) was drawn from
the entire InGef database. For 3,695,024 of those insured persons
complete data of the observational period between 2013 and
2015 (including death in 2015) was available and served as study
population.
The study protocol and the results of this study were reviewed
and discussed with a group of German PD experts composed of
hospital neurologists and neurological practices, as well as two
German patient organizations (Supplementary Material, online
only). Due to the anonymized nature of the data, an informed
consent of the study participants and a vote of an external ethic
committee were not required.
Study Design and Study Population
The present study was designed as a retrospective cohort study
to estimate the population-based prevalence and incidence
of PD per 100,000 persons in Germany in 2015. Moreover,
we compared the prevalence of (co-)occurring symptoms and
diseases, mortality, and utilization of healthcare resources
between prevalent PD cases and individuals without PD.
Subjects were eligible to enter the cohort if they fulfilled the
following inclusion criteria: (1) continuous insurance in 2015 or
until death, (2) a diagnosis of PD (ICD-10 G20 code) in 2015
(see berrlow), (3) continuous insurance or birth in 2013 and 2014
(baseline period), and (4) absence of a diagnosis of PD in the
baseline period (only for calculation for the incidence).
Prevalent cases of PD fulfilled one of the following criteria in
2015: (1) Main hospital discharge diagnosis of PD (which can
be considered as the main medical reason for hospitalization),
(2) at least two diagnoses of PD in two different quarters,
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(3) PD diagnoses by at least two different physicians, and/or
(4) at least one diagnosis of PD and at least one prescription
for an antiparkinsonian (anti-PD) medication (ATC codes
N04Bx) in 2015 (see flow-chart in Figure 1). Only primary and
secondary hospital diagnoses and verified ambulatory diagnoses
were considered. As suggested previously (11, 12), we aimed
to increase validity of ambulatory diagnoses by at least one
subsequent PD diagnosis and by an additional anti-PD drug
prescription in 2015. Supporting the validity of the PD diagnosis
79% of prevalent PD cases and 59% of incident PD cases fulfilled
more than one of these criteria (Supplementary Material, online
only).
To compare diseases/complications and mortality, as well
as medications, other treatments and health services between
PD patients and insured persons without PD, an age- and sex-
matched control group (1:1 matching) without a PD diagnosis in
2015 was selected.
Definitions of (Co-)occurring
Diseases/Complications, Mortality,
Treatments, and Healthcare Services
Pre-defined (co-)occurring complications/symptoms and
diseases frequent in the elderly and/or in PD patients (where
their co-occurrence may partly be considered a co-morbidity)
were identified based on primary or secondary hospital diagnosis
or verified ambulatory diagnosis as defined by ICD-10 codes.
The prevalence of diabetes, dementia, depression, hypertension,
cancer, sleeping disorders, fatigue, bladder dysfunction and,
sexual dysfunction are reported. Patients who deceased in 2015
were identified based on death as reason for disenrollment from
the insurance.
Prescriptions of any medication and of different medications
(i.e., compounds) were identified based on ATC codes. Anti-
PD medications were identified based on “N04Bx” ATC codes
while 7-digit ATC codes quantified the number of different
of anti-PD medications used in 2015. Moreover, for each
prescription the specialty of the prescribing physician was
indicated. Furthermore, health claims of therapeutic remedies
and aids were specified and quantified. Definitions and codes of
all variables are provided in the Supplementary Material (online
only).
Statistical Analysis
Prevalence and incidence of PD per 100,000 persons were
calculated stratified by sex and age groups (0–17, 18–29, 30–39,
40–49, 50–59, 60–64, 65–69, 70–74, 75–79, 80–84, 85–89, and
90+ years), by dividing the absolute number of PD cases by the
number of cohort subjects (or the respective stratum) in 2015.
For the prevalence and incidence of PD, 95% confidence intervals
were calculated assuming a binominal distribution. In addition,
the overall prevalence and incidence were standardized according
to the age, sex, and regional distribution (i.e., federal states) of
the total German population in 2015 (82.2 million). Differences
between controls and PD cases were statistically tested using
Mann–Whitney U tests for continuous variables and Chi-square
tests for categorical variables. Statistical analyses were performed
using SAS Enterprise Guide, version 4.3.
RESULTS
Prevalence and Incidence of PD
Overall, 21,714 prevalent PD cases were identified. PD cases were
slightly more frequently male (50.8%) than female (49.2%) and
had a mean age (± standard deviation) of 77.8 ± 9.3 years.
Males (76.6 ± 9.2 years) were slightly younger than females
(79.0 ± 9.1). The crude prevalence of PD in 2015 was 587.7 per
100,000 persons (95%-confidence interval: 579.8–595.5) and the
standardized prevalence per 100,000 persons was 511.4 (504.6–
518.2). The prevalence and incidence of PD stratified by age and
sex are shown in Figures 2A,B and the Supplementary Tables 1,
FIGURE 1 | Flow-chart of PD case identification criteria. Of the four different criteria at least one had to be fulfilled in prevalent PD cases in 2015.
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2 (online only). Males showed a higher prevalence of PD than
females at all ages. The statistical projection to general population
indicates an overall prevalence of 420.371 PD cases in Germany.
The crude incidence of PD per 100,000 persons in Germany
in 2015 stratified by age and sex is shown in Figure 2C. In 2015,
3,541 incident PD cases were identified corresponding to an
overall crude incidence of 95.8 per 100,000 persons (92.7–99.0)
and a standardized incidence of 84.1 (95%-confidence interval:
81.3–86.9). Incident PD cases were slightly more frequently
male (52.2%) than female (47.8%). The mean age (± standard
deviation) was 76.4 ± 9.7 years while males (75.7 ± 9.5) were
younger than females (77.1 ± 9.9). The statistical projection to
general population of Germany indicates an overall incidence
of 69,130 PD cases in Germany in 2015. The first diagnosis
of PD in incident cases was made by medical professionals
of a variety of institutions, i.e., resident physicians [including
neurologists, general practitioners (GP)], ambulatory physicians,
hospitals/clinics, or other institutions/professionals. The relative
frequencies of these medical institutions and professionals
determining the first PD diagnosis are shown in Figure 3.
(Co-)occurring Diseases, Complications,
and Mortality in PD
In particular, dementia, depression, bladder dysfunction, fatigue
and sleeping disorders showed a markedly higher prevalence
in PD patients compared to controls. PD patients showed also
higher prevalence (PD>controls) for diabetes and hypertension.
Sexual dysfunction differed only marginally between cohorts,
whereas for cancer no difference was observed (Table 1).
Moreover, an annual mortality of 10.7% in PD patients
(N = 2,330 deceased in 2015) was observed, which was
significantly (p < 0.001) higher than for persons in the control
group (N = 1.264 deceased; 5.8%). The mortality ratio was 1.84
in PD patients relative to controls.
Prescription of Medications
Generally, number and diversity of prescribed medications
differed between prevalent PD cases and controls (Table 2).
PD cases had a 42 and 31% higher number of overall and
different number of prescriptions, respectively, than controls.
The majority of PD patients (78%) were prescribed anti-PD
drugs, yet 22% of PD patients did not receive any prescription of
anti-PD drugs. Between PD patients a large variability regarding
the total number of anti-PD prescriptions and the number of
different anti-PD drugs was observed.
In 66% of PD patients anti-PD drug prescription were at
least once made by a neurologist in 2015, whereas in 34% of
PD patients no neurologist was involved in the prescription of
anti-PD drug prescriptions (Table 3).
Treatments and Healthcare Utilization
Compared to controls, PD patients were treated by a higher
number of physicians (20%, 1.2 more physicians), and had
a higher overall number of physician contacts (25%, 3.0
more physician contacts) in 2015. The numbers of GP and
psychiatrist contacts were similar between PD patients and
controls, whereas treatment by a neurologist occurred more
FIGURE 2 | The prevalence and incidence of Parkinson’s disease in Germany
in 2015. Stratified by age groups and sex (A) the percentages of prevalent
Parkinson’s disease (PD) cases (within sex groups percentages add up to
100%), (B) the crude prevalence of PD per 100,000 persons, and (C) the
crude incidence of PD per 100,000 persons in Germany in 2015 are shown.
than twice a year in PD patients and only 0.3 times per
year in controls. Hospital treatment in general was more
frequent in PD patients compared to controls. Here, nearly
two-fold higher numbers of hospitalizations and total days
of hospital treatment in PD patients compared to controls
were observed (Table 4). The utilization of other forms
of treatment and healthcare services is shown in Table 5.
Treatments and support as indicated by therapeutic remedies
and aids were provided more frequently for PD patients
(in about half of all PD patients) compared to controls
(15–30%). More than one third of PD patients was treated
with physical therapy, whereas speech therapy, occupational
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FIGURE 3 | The first diagnosis of PD. Type of physician or medical institution
(in percent) giving an initial diagnosis of Parkinson’s disease in incident cases.
TABLE 1 | (Co-)occurring diseases and complications.
Diagnosis PD Controls P-value
Bladder dysfunction 9.937 (46%) 4.796 (22%) <0.001
Cancer 4.672 (22%) 4.792 (22%) >0.1
Dementia 8.506 (39%) 2.845 (13%) <0.001
Depression 9.807 (45%) 4.766 (22%) <0.001
Diabetes 7.679 (35%) 6.782 (31%) <0.001
Fatigue 2.186 (10%) 1.317 (6%) <0.001
Hypertension 16.951 (78%) 16.501 (76%) <0.001
Sexual dysfunction 838 (4%) 738 (3%) 0.003
Sleeping disorders 4.414 (20%) 2.670 (12%) <0.001
Values indicate the number (percentage) of persons with (associated)
diseases/complications.
therapy and psychotherapy were relatively rarely prescribed.
Complex treatment regimes, such as apomorphine/pump
treatment, deep brain stimulation (each <0.1%), and diagnostic
polysomnography (2%) were rarely (newly) prescribed in PD
patients.
DISCUSSION
This study provides recent epidemiological estimates of
standardized prevalence and incidence of PD based on
representative statutory insurance claims data in Germany in
2015. Moreover, the analysis provides the recent prevalence
of associated diseases and complications, as well as up-to-date
quantifications of the healthcare utilization of PD patients and a
control population.
Prevalence and Incidence of PD
Results of studies reporting crude and standardized prevalence
and incidence of PD differ widely (8, 15). While global
and regional differences in the epidemiology of PD may
exist (8), inconsistencies between studies may often be due
to methodological differences inherent to data sources and
definitions of PD case ascertainment that vary in sensitivity and
specificity.
In Germany, a standardized prevalence of 797 and
961/100,000 PD cases (year 2004 and 2007), and a standardized
TABLE 2 | Prescribed drugs for patients with Parkinson’s disease and controls.
Drug prescription status PD patients Controls
Persons with any drug
prescription
100% 94%
Total prescriptions [mean
number per year (SD)]
37.7 (24.2) 21.7 (19.6)
Number of different drugs
[mean number per
year (SD)]
10.8 (5.6) 7.4 (5.3)
Persons with prescription of
anti-PD drugs
78% 2%
Total anti-PD drug
prescriptions [mean number
per year (SD)]
7.4 (7.4) 0.1 (0.7)
Persons by number of differing anti-PD drug prescriptions
0 anti-PD medications
1
2
3
4
5+
22%
42%
21%
9%
3%
1%
98%
2%
0%
0%
0%
0%
TABLE 3 | Prescription of anti-PD medication by physician groups in 2015.
Physician groups prescribing anti-PD medication PD patients
Patients with anti-PD drug prescription 16.842 (100%)
Only by neurologist 6.686 (40%)
Only by GP 3.951 (23%)
GP and neurologist 3.731 (22%)
Specialist of other medical disciplines 711 (4%)
GP and specialist of other medical disciplines 560 (3%)
Neurologist and specialist of other medical disciplines 746 (4%)
Only specialist of other medical disciplines 457 (3%)
GP, General practitioner; PD, Parkinson’s disease.
incidence of 192–229/100,000 person-years (2004–2010)
based on statutory insurance claims data of the “Allgemeine
Ortskrankenkasse” (AOK) and criteria of repeated PD diagnosis
(in- and outpatient) and PD diagnosis confirmed by anti-
PD medication have been reported (12). In comparison, the
standardized prevalence of 511/100,000 and standardized
incidence of 84/100,000 persons as shown in the present
study are markedly lower. These inconsistencies might be best
explained by methodological differences. Unlike the InGef
research database (14) used in the present study, the AOK
database only included persons with 50+ years of age and
overall reported higher mortality rates than the age-stratified
general German population (12). Also, regional and potential
socioeconomic differences between samples might underlie the
higher PD prevalence and incidence rates in the AOK data.
Insurance claims data in France from 2010 showed, using
specific and sensitive PD criteria, respectively, a substantially
lower standardized PD prevalence and incidence compared with
our findings, i.e., 308–410 PD cases/100,000 persons and annual
incidence rates of 36–49 PD cases/100,000 persons. In Italy, a
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TABLE 4 | Physician contacts and hospital treatment in 2015.
Type of medical healthcare PD patients Controls
Number of different physicians 7.3 (3.8) 6.1 (3.7)
Total physician contacts 15.2 (7.6) 12.2 (7.3)
GP contacts 5.0 (2.5) 4.5 (2.5)
Neurologist contacts 2.2 (1.9) 0.3 (0.9)
Psychiatrist contacts 0.2 (0.9) 0.1 (0.5)
Any (inpatient) hospital treatment 49% 30%
Hospitalizations 1.0 (1.4) 0.5 (1.1)
Hospital days 9.8 (19.4) 4.8 (14.1)
Mean (standard deviation) or percent of total are indicated.
TABLE 5 | Other treatments, diagnostic measures and healthcare services in PD
patients and controls.
Healthcare claims PD patients Controls
Aids 47% 30%
Any therapeutic remedy 58% 28%
Physical therapy 36% 2%
Speech therapy 4% <0.4%
Occupational therapy 6% 1%
Psychotherapy 1% <0.1%
Apomorphine treatment <0.1% <0.1%
Pump treatment <0.1% <0.1%
Deep brain stimulation <0.4% <0.1%
Complex treatment 2% <0.1%
Polysomnography 2% 1%
Residential care 21% 6%
standardized prevalence of 233 PD cases/100,000 persons and
standardized incidence rate of 23.1 PD cases/100,000 persons
based on primary care data from 2013 have been shown (16).
Thus, large differences in epidemiological estimates of PD exist
between studies and countries. The rather conservative PD
definition (11) and the external validity of the data basis (14)
suggest a realistic representation of the epidemiology of PD
in Germany in 2015 with a projected prevalence of 420,371
PD patients and a projected incidence of 69,130. However,
several limitations inherent to insurance claims data have to be
considered (see below). The present estimates are substantially
higher than the projected prevalence of 219,579 PD patients
in Germany referred to by the European Brain Council in
2010 (13) that however was projected from prevalence estimates
reported for France, Italy, Spain, and UK. This outdated estimate,
that is not specific for Germany, is still “officially” reported
(7).
In about one quarter of incident PD cases the first
diagnoses was made solely by residential neurologists and one
quarter by residential general practitioners, whereas about one
half was first diagnosed by other institutions (i.e., hospitals
or ambulatory physicians) and other medical professionals.
Thus, similar to previous findings (12) a large percentage
of PD patients received the initial diagnosis by professionals
other than neurologists. Previously, confirmation rates of
PD diagnoses based on post-mortem histopathology of 74%
for non-experts, and 80–84% for medical specialists have
been shown (17). While misdiagnoses of PD may lead to
an overestimation of the prevalence and incidence of PD,
the number of PD cases who remain undiagnosed is also
unknown. The extent to which these aspects contribute to
an over- or underestimation of the prevalence and incidence
of PD has to be further investigated, e.g., based on long-
term longitudinally confirmed PD diagnoses, and age of PD
onset and PD severity data that may indicate delayed PD
diagnoses.
(Co-)occurring Diseases/Complications,
and Mortality in PD
PD often presents as a more complex and heterogeneous clinical
phenotype than defined through its cardinal motor symptoms
alone. Accordingly, a high prevalence of several PD-associated
diseases and complications was observed. Numerous other
studies (4–6) already showed non-motor diseases/complications
to be frequent in PD and for some of these the present study
showed an even higher prevalence. Among the preselected
diseases/complications, dementia was diagnosed in 39% of PD
patients and 13% of controls, which was higher than 25–30%
prevalence of dementia in PD patients reported previously
(18, 19). Depression was diagnosed in 45% of PD patients
and 22% of controls, whereas German secondary insurance
claims data previously showed a prevalence of depression in
33% of PD patients (11). While in meta-analysis a similar
overall prevalence of depression in PD was observed the study
also showed large heterogeneity in findings and methodological
differences suggesting that prevalence estimates based on
different studies might not be exact (20). Bladder dysfunction
was also substantially more frequent in PD patients (46%)
than controls (22%). Similarly, another study reported about
a two-fold relative risk of bladder symptoms in PD patients
compared to controls (21), confirming bladder dysfunction as
a major complication in PD. Sleeping disorders were observed
in 20% of PD patients and 12% of controls. This prevalence
in PD is low compared to previous reports (22), but unlike
specific clinical studies sleeping disorders may not be assessed
or coded in many medical practices. Thus, claims data may
not represent the actual prevalence of sleeping disorders in
PD. A similar explanation may apply for fatigue (10% of PD
patients), which differed in prevalence from previous findings
[about one third of PD patients (23)]. Hypertension was very
frequent in PD (78%) as well as controls (76%). Possibly
more specific aspects, e.g., orthostatic hypotension, might show
larger differences between PD and controls. Consistent with
a meta-analysis of associations between PD and diabetes (24)
PD patients (35%) were more often diabetics than controls
(31%). Cancer prevalences did not significantly differ between
PD patients and controls. However, cancer types were not
differentiated which should be considered since melanoma may
increase, whereas other types of cancer may decrease the PD risk
(25).
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Importantly, PD-associated diseases, such as depression,
dementia and autonomous dysfunction, may exert a larger
impact on quality of life in many PD patients than the
characteristic PD motor symptoms (26).
In the present study, the mortality rate in PD patients was
almost twice as high as in controls. A meta-analysis showed
standardized mortality ratios ranging from 0.9 to 3.8 (pooled
mortality ratio: 1.4) (27), thus the mortality ratio of 1.84 in the
present study was within the mid-range of previous reports.
Medical Healthcare Utilization
The number of different prescriptions was generally high but
realistic for an elderly population in Germany. PD patients
were prescribed a relatively low mean number of 1.3 different
anti-PD drugs with however large differences between patients.
PD patients (22%) often did not receive any anti-PD drugs,
although the treatment guidelines recommend pharmacological
treatment in early-stage PD (7). Some of these PD patients might
still be under observation (before a definite PD diagnosis) or
might have secondary Parkinsonism, e.g., vascular Parkinsonism,
without anti-PD medication prescriptions. A vast number
of PD patients (42%) was treated with a monotherapy,
which might be adequate for some PD patients (e.g., de-
novo PD, advanced age), while some may benefit from a
more differentiated anti-PD medication plan. However, the
exact L-dopa equivalent daily dose (LEDD) could not be
calculated from the insurance claims data, yet longitudinal
changes in prescribed medication (with increasing disease
severity) constitute an interesting outcome of longitudinal
studies.
The prescription of anti-PD drugs in 2015 was in only
40% of PD patients exclusively made by neurologists, and
did in 67% of PD patients involve a neurologist at least
once (in addition to other medical professionals). However,
PD patients would benefit from an annual consultation of a
neurologist, since PD specialist may best adjust treatments under
consideration of (changing) factors and (non-)motor symptoms
(7, 28). In 2015, PD patients only had three physician contacts
more than controls. The higher prevalence of comorbidities in
PD than controls and PD-specific demands of treatment and
specialist consultation suggests this difference to be relatively
low. PD patients consulted neurologists on average 2.2 times
per year however as indicated by the standard deviation of 1.9
neurologist contacts large heterogeneity was observed between
PD patients. Some evidence suggests that neurologist treatment
is associated with higher survival rates, lower rates of hip-
fractures and lower nursing home placements compared to non-
specialist treatment (29). However, themere number of physician
contacts might only provide incomplete measure of the medical
services. Hospital admissions were more frequent in PD patients
compared to controls (49/30% of individuals), however hospital
days showed large variance. Possibly hospital treatment due
to accidents might have been prevented in some PD patients
if optimal PD treatment and management had been provided
(29).
Aids were provided for less than half of PD patients (47%)
and 30% of controls. Aids can constitute highly relevant means
of support, but the individual demands and insurance coverage
of aids might differ between PD patients.
More than 42% of PD patients were not prescribed therapeutic
remedies. In particular, only 36% of PD patients had physical
therapy, despite growing evidence showing beneficial effects
of exercise on various aspects of daily living in PD patients
(30). Complex treatments (2%), and (new prescriptions of)
infusion pumps and deep brain stimulation (<0.1%) were
relatively rare. Residential care was more often required for
PD patients (21%) than for controls (6%), but to what extent
decreased mobility or (co-)occurring diseases/complications
underlie the demand for residential care needs to be further
investigated.
Limitations
Several limitations of the present study have to be considered.
(1) The insurance claims data was standardized to the general
population regarding age, sex, and region, and thus for these
factors the present study can be considered representative.
However, other factors including socio-economic status
could not be accounted for, which may partly limit the
representativeness. (2) The accuracy of PD diagnosis might
differ between professionals, and we therefore employed
several approaches to decrease the rate of false-positive PD
cases, e.g., through repeated/independent PD diagnosis or
diagnosis confirmed by anti-PD medication criteria. (3)
Reported estimates may partly represent an “administrative”
prevalence and incidence as in some cases the PD diagnosis
might have been given due to reasons of reimbursement.
Thus, insurance claims data may partly be biased toward
overestimating epidemiological estimates of PD. (4) As not
covered by insurances, additional treatments/services as needed
by PD patients might not be identified through insurance claims
data.
Claims data constitute a valuable data source for up-
to-date longitudinal observational studies in (prodromal)
PD research. Based on this data, diagnoses and insurance
claims that were made (many) years after (or before)
the PD diagnosis can be analyzed regarding temporal
sequences of diagnoses, medication and healthcare utilization
in PD and/or in groups defining possible PD subtypes.
Moreover, PD can be defined as a syndrome and not one
disease entity (31), and may be embedded within disease
networks with overlapping disease characteristics. Due to
the comprehensive availability of diagnoses, treatments,
and healthcare utilization across all medical disciplines,
insurance claims are a promising data source to address
contemporary and complex research questions in medical
sciences.
We believe the present study encourages a rethinking of the
epidemiology and healthcare utilization in PD: (1) Compared to
previous reports, substantially higher prevalence and incidence
of PD in Germany in 2015 were observed in this comprehensive
analysis of insurance claims data. Here, PD cases below the
age of 50 years, i.e., early onset PD, were also considered and
a both sensitive and specific case identification strategy was
applied. (2) While largely consistent with previous findings, the
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co-occurrence of non-motor symptoms and complications was
very frequent in PD patients. Yet, while motor as well as non-
motor symptoms often pose substantial healthcare demands,
large variability between PD patients regarding the number of
treatments and medications was observed. Possibly, many PD
patients would benefit from additional and holistic healthcare
utilization. Basic and clinical PD research continue to require
political, societal and industry support. However, the agendas
of PD research as well as healthcare policy making should both
consider changes in the epidemiology of PD and individual needs
of PD patients.
CONCLUSION
The projected standardized prevalence of PD in the present study
was nearly two-fold higher than suggested by previous “official”
estimates. Several associated diseases and complications
including dementia, depression, diabetes, and bladder
dysfunction known to pose additional burden to PD patients
and to require additional healthcare were highly frequent in PD
patients. The healthcare utilization differed strongly between
PD patients, and demands of substantial and holistic treatment
and support for many PD patients are possibly unmet so far.
Longitudinal studies of insurance claims data are needed to
investigate the individual and epidemiological progression of PD
and (holistic) healthcare demands of PD patients.
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